In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer

Zeyu Chen(Kingmed Diagnostics), Junwei Shi(University of Pennsylvania), Viktoriya Ekshyyan(Translational Therapeutics (United States)), Jennifer E. Wu(Parker Institute for Cancer Immunotherapy), Nancy A. Speck(University of Pennsylvania), Makoto Kurachi(University of Pennsylvania), Kito Nzingha(Translational Therapeutics (United States)), Omar Khan(University of Pennsylvania), Shelley L. Berger(University of Pennsylvania), Divij Mathew(Parker Institute for Cancer Immunotherapy), Zhendong Cao(University of Pennsylvania), Mohamed S. Abdel-Hakeem(Emory University), Shin Foong Ngiow(Parker Institute for Cancer Immunotherapy), Qingzhou Chen(University of Pennsylvania), E. John Wherry(Parker Institute for Cancer Immunotherapy), Zhuoyu Wen(Northwest Women's and Children's Hospital), Zhangying Cai(University of Pennsylvania), Alexis Battle(Barcelona Institute of Science and Technology), Allison R. Greenplate(California University of Pennsylvania), Josephine R. Giles(Parker Institute for Cancer Immunotherapy), Amy E. Baxter(Translational Therapeutics (United States)), Hua Huang(Shaoxing University), Sasikanth Manne(Translational Therapeutics (United States)), Yuan He(Baogang Group (China)), Zhen Zhang(Shanxi Medical University), Eri Arai(University of Pennsylvania), Mohammed A. Ali(Translational Therapeutics (United States)), Elizabeth Freilich(University of Pennsylvania)
Cell
February 25, 2021
Cited by 217


Related Papers